Antimicrobial Pharmacokinetics in Critically Ill Adults During Sustained Low Efficiency Dialysis (SLED)
NCT02242006
Critical Illness, Disease Attributes
Ottawa, Ontario, Canada
View Trial DetailsNCT Number: NCT03560557
WP1.1. PK/PD target attainment: Plasma exposure, Excretion via urine & ELF exposure; WP1.2. Predictive dosing algorithm; WP1.3. ECMO subset
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
First, the investigators will document exposure to meropenem in plasma and epithelial lining fluid. Moreover excretion in urine will be documented.
Second, the investigators will try to identify risk factors for not attaining PK/PD target. Based on significant predictors for target non attainment a predictive dosing algorithm will be constructed.
Finally in a small subset of ECMO patients PK exposure will be explored.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: on day of sampling
risk factors will be assessed by comparing patients who attain target vs. those who don't
Universitaire Ziekenhuizen KU Leuven
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02242006
Critical Illness, Disease Attributes
Ottawa, Ontario, Canada
View Trial DetailsNCT03438981
Blood Protein Disorders, Critical Illness
Leuven, Belgium
View Trial DetailsNCT04612348
Critical Illness, Disease Attributes
Columbus, Ohio, United States
View Trial DetailsNCT03195127
Chronic Disease, Critical Illness
Baltimore, Maryland, United States
View Trial Details